Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Getty%20image%20doctor_0.jpg

The Best Prescription

The craziest question that you can ask any doctor is “what is your best therapy for __?”.    Crazy, because there are exponential answers, with factored layers that make each decision unique to that doctor. Each doctor has her own cha-cha-cha algorithm to a particular problem. The problem is, we each dance to a different cha-cha-cha tune in the practice of medicine.

Read Article
GCA,woman

2022 ACR/EULAR Giant Cell Arteritis Classification Criteria

Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology.

Read Article
hidradenitis.jpg

Inflammatory Arthritis and Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by

Read Article
RheumNow Podcast square

Biosimilar Bonanza in 2023 (12.9.2022)

Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com. 

Read Article
Video computer laptop call telehealth telemedicine

Telemedicine Updates

Several recent articles inform us of recent trends in Telemedicine.

Read Article
us-capitol-477987_640.jpg

ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth

As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R.

Read Article
PSA068.jpg

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

Read Article
PSA2L.jpg

The Top 10 Research Priorities in Psoriatic Arthritis

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

Read Article
genes_0.jpg

Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis

The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied. 

Read Article
cardiac2.jpg (keep)

TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis

A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).

Read Article
×